Tesamorelin Cycle vs Continuous: On/Off Protocols, IGF-1 Desensitisation Evidence, and Where to Buy in the UAE (2026)

Why This Question Matters

Tesamorelin is a stabilised GHRH(1–44) analogue developed by Theratechnologies and approved by the FDA in 2010 (brand name Egrifta) for HIV-associated lipodystrophy. Outside the HIV indication, researchers use tesamorelin to study visceral adipose tissue (VAT) reduction, lipid profile, IGF-1 axis modulation, and — more recently — non-alcoholic fatty liver disease (NAFLD/MASH) endpoints.

The cycling question is one of the most contested topics in tesamorelin research: should daily 2 mg subcutaneous injections be run continuously, or should researchers cycle on and off to "protect" the GHRH receptor and avoid IGF-1 desensitisation? This guide unpacks what the Falutz long-term trials actually show, where the desensitisation hypothesis comes from, and how to source pharmaceutical-grade tesamorelin in the UAE with 24h delivery.

The Falutz Continuous-Dosing Data

Three Falutz-led trials form the evidentiary backbone for continuous tesamorelin dosing. They are unusual in the GHRH-analogue literature because they followed subjects beyond the conventional 12-week window most peptide trials stop at.

Falutz 2007 (NEJM) — 26-week core trial

• n = 412 HIV-positive subjects with excess abdominal fat
• 2 mg tesamorelin SC daily vs placebo for 26 weeks
• VAT reduced 15.2% vs +5.0% placebo (p<0.001)
• IGF-1 rose ~81% and stayed elevated throughout
• No tachyphylaxis observed at week 26

Falutz 2008 (JCEM) — 52-week extension

• Subjects who completed Falutz 2007 continued for an additional 26 weeks
• VAT reduction maintained with continued daily dosing
• Subjects re-randomised to placebo lost the VAT benefit within 26 weeks
• IGF-1 remained elevated in the continuous group at week 52

Falutz 2010 (AIDS) — pooled long-term safety

• Pooled data from two parallel 26-week phase 3 trials with 26-week extension
• Long-term continuous dosing was well tolerated through 52 weeks
• No accumulating receptor desensitisation signal
• Discontinuation predominantly reversed the VAT and IGF-1 effects

The clinical takeaway from Falutz is uncomfortable for cycling proponents: 52 weeks of continuous daily 2 mg tesamorelin produced sustained pharmacodynamic effect with no demonstrable loss of efficacy. There is no published continuous-vs-cycled head-to-head trial — cycling is folklore, not evidence.

Where the IGF-1 Desensitisation Hypothesis Comes From

The cycling rationale is mostly inherited from three adjacent observations:

1. GHRH receptor downregulation in cell-line studies. In-vitro pituitary somatotroph cultures show receptor internalisation under continuous GHRH stimulation. This is real at the cellular level but does not appear to translate to clinically meaningful pituitary tachyphylaxis in the Falutz trials.
2. Sermorelin / GHRP-2 / GHRP-6 cycling traditions. Bodybuilding-era short-half-life GHRHs and GHRPs (Lee and colleagues described GHRP-6 in the 1980s) developed empirical 5-on/2-off and 8-weeks-on/4-off protocols. These were never validated and were largely about cost-management, not pharmacology.
3. The IGF-1 saturation argument. Some researchers argue that maintaining IGF-1 in the upper-normal range continuously may carry hypothetical long-term risks (insulin resistance, theoretical neoplasia risk in those genetically predisposed). The current data do not support a clinical signal in tesamorelin trials but the theoretical concern persists.

None of these three lines of reasoning produced a randomised tesamorelin trial that showed cycling preserves efficacy better than continuous use. The cycling literature for tesamorelin is essentially empirical.

Common Empirical Cycling Protocols (Not RCT-Validated)

If a researcher chooses to cycle despite the Falutz evidence, three empirical patterns dominate the literature outside of published RCTs. None are validated. They are presented for completeness only.

What Continuous Dosing Actually Looks Like — Practical Schedule

The published Falutz protocol that REVIVE researchers most commonly reference is straightforward:

• Dose: 2 mg SC, once daily
• Timing: Evening, at least 2 hours after the last meal — aligns with the physiological nocturnal GH pulse
• Injection site: Abdominal SC, rotated to minimise local lipoatrophy / lipohypertrophy
• Reconstitution: Bacteriostatic water; 5 mg vial + 2 mL BAC = 2.5 mg/mL (draw 0.8 mL for 2 mg dose). See our peptide reconstitution guide
• Monitoring cadence: Baseline IGF-1, 12-week IGF-1, 26-week IGF-1 + VAT imaging if available
• Discontinuation: Falutz 2008 showed VAT benefit reverses within 26 weeks of stopping — continuous dosing was the design assumption

The IGF-1 Monitoring Argument For Periodic Pauses

Some researchers favour a hybrid approach: run continuous dosing as Falutz did, but monitor IGF-1 every 12 weeks and pause if IGF-1 exceeds the upper third of the age-adjusted reference range. This is more defensible than fixed-calendar cycling because it ties the pause decision to a measurable biomarker rather than folklore.

Stanley and colleagues (Stanley 2014 JAMA, Stanley 2019 Lancet HIV) extended the Falutz work into NAFLD endpoints and continued to use continuous daily dosing with IGF-1 monitoring rather than calendar-based cycling. Their NAFLD trial showed continuous 2 mg daily for 12 months reduced liver fat fraction by ~30% in HIV-associated NAFLD — again with no efficacy decay over the year.

UAE Delivery & Sourcing — Where to Buy Tesamorelin in the UAE

REVIVE LAB holds tesamorelin in stock in a Dubai cold-chain warehouse. Researchers ordering tesamorelin from the UAE benefit from no international transit, no customs delay, and no thermal excursion risk during shipping. Same-day Dubai dispatch is standard for orders placed before 2pm UAE time.

Delivery Windows by Emirate

Why Local UAE Stock Matters for Tesamorelin

• Lyophilised tesamorelin is heat-sensitive in transit. International shipments routinely sit on Gulf tarmacs in summer; local Dubai stock eliminates the worst exposure window.
• Reconstituted vials are 28-day stability-limited at 2–8°C. See our UAE peptide storage guide.
• HPLC certificate per batch. Each REVIVE tesamorelin vial ships with a batch-matched purity certificate.
• UAE-stocked vials, UAE-issued invoice. No cross-border customs paperwork for researchers.

REVIVE Tesamorelin Stock — Confirmed SKUs

• Tesamorelin 5 mg/vial — standard research SKU
• Tesamorelin 10 mg/vial — multi-dose research SKU
• Pair with Bacteriostatic Water 3 mL for reconstitution

Browse the full UAE-stocked range at peptides UAE, or go directly to the tesamorelin product page (buy tesamorelin UAE 24h delivery).

Decision Framework — Cycle or Continuous?

1. Default to continuous if your endpoint matches Falutz / Stanley. VAT reduction, lipid profile, NAFLD liver-fat fraction — all RCT-supported with continuous daily 2 mg.
2. Consider continuous + biomarker-gated pause if IGF-1 is your concern. Test at baseline, 12 weeks, 26 weeks. Pause if IGF-1 exceeds age-adjusted upper third.
3. Calendar-based cycling is the weakest option. No human RCT data support 5-on/2-off, 8-on/4-off, or 12-on/4-off patterns as superior to continuous use.
4. Document the rationale. Whichever protocol you choose, log the reasoning — clinical research practice expects justification.

Practical UAE-Specific Considerations

• Evening dosing window: UAE summer outdoor activity tends to push dinner later. Inject 2 hours after the last meal to align with the nocturnal GH pulse window.
• Refrigeration during summer power events: Keep reconstituted vials in the main fridge body, not the door, to buffer brief opening/closing thermal swings.
• Ramadan timing: Researchers fasting in Ramadan may shift injection to post-iftar; maintain the 2-hour post-meal interval where feasible.
• Travel within GCC: Reconstituted tesamorelin should travel in a cold pack; lyophilised vials tolerate brief room-temperature transit but should be refrigerated on arrival.

Frequently Asked Questions

Where can I buy tesamorelin in the UAE with 24h delivery?

REVIVE LAB ships tesamorelin 5 mg and 10 mg vials from Dubai stock with 24h delivery across the UAE — same-day to Dubai, next-day to Abu Dhabi, Sharjah, Ajman, RAK and Fujairah. Order before 2pm UAE time for same-day Dubai dispatch.

Should tesamorelin be cycled or run continuously?

The strongest human evidence (Falutz 2007, 2008, 2010) supports continuous daily 2 mg SC dosing for 26 to 52+ weeks with sustained VAT reduction and sustained IGF-1 elevation. No published trial shows on/off cycling outperforms continuous use. Cycling is empirical, not evidence-based.

Does tesamorelin desensitise the GHRH receptor in humans?

Falutz long-term data through 52 weeks show sustained IGF-1 elevation and sustained VAT reduction with no evidence of pituitary tachyphylaxis. Concerns about receptor desensitisation are theoretical and extrapolated from in-vitro work and other GHRH analogues — not confirmed in tesamorelin clinical trials.

How fast does REVIVE deliver tesamorelin to Abu Dhabi or Sharjah?

Tesamorelin orders to Abu Dhabi ship next-day from REVIVE's Dubai cold-chain warehouse (24h delivery). Sharjah is typically same-day or next-day depending on cut-off time. Tesamorelin is held in stock in the UAE — no international transit, no customs delay.